Diagnosis and Management of Inherited Platelet Disorders

Carl Maximilian Kirchmaier  Daniele Pillitteri

Deutsche Klinik für Diagnostik, Sektion Innere Medizin I, Arbeitsgruppe: «Thrombose, Hämostase und vaskuläre Medizin», Wiesbaden, Germany

Keywords
Inherited platelet function disorders · Diagnosis · Therapy

Introduction
In clinical daily routine it is quite difficult to detect pathological bleeding tendencies. Physicians are often confronted with patients suffering from apparently excessive or frequent unprovoked bleeding, most commonly epistaxis or menorrhagia, or at parturition. The most common cause of bleeding is the disorder of primary hemostasis, in particular defects of platelet function (thrombocytopathy). Even though inherited thrombocytopathies are much less frequent in clinical practice than acquired thrombocytopathies [1], they deserve special attention because inherited platelet disorders are usually more severe bleeding tendency and are often not diagnosed. They are induced by different platelet defects based on disorders of platelet adhesion, receptors, secretion, and signal transduction. In some cases, they are associated with thrombocytopenias, giant platelets, and various comorbidities. This article gives an overview of the different defects, their diagnosis, and treatment options.

Schlüsselwörter
Angeborene Thrombozytenfunktionsstörungen · Diagnostik · Therapie

Summary
In clinical daily practice the definition of a bleeding tendency is rather subjective. Clinical manifestations usually include hematoma, epistaxis, menorrhagia, and severe bleeding episodes after surgery or injuries. The most common causes are disorders of primary hemostasis that occur sometimes due to platelet function disorders. Inherited thrombocytopathies are much less frequent in comparison to acquired platelet function disorders. However, congenital disorders can lead to severe bleeding tendency and are often not diagnosed. They are induced by different platelet defects based on disorders of platelet adhesion, receptors, secretion, and signal transduction. In some cases, they are associated with thrombocytopenias, giant platelets, and various comorbidities. This article gives an overview of the different defects, their diagnosis, and treatment options.
serious regarding the bleeding tendency. Inherited thrombocytopenias are related to different platelet defects, including defects of platelet adhesion, receptors, secretion, signaling pathways, and enzymes [2–7]. In addition, some platelet function disorders may be associated with thrombocytopenia, giant platelets, and/or typical comorbidities. In the first part of this article, a survey is given on the most common inherited thrombocytopenias. A simplified classification is shown in table 1. Afterwards, we discuss the diagnosis and management of those platelet disorders.

### Specific Disorders of Platelet Function

#### Defects of Platelet Receptors

**Glanzmann Thrombasthenia**

Glanzmann thrombasthenia (GT) is a rare, autosomal-recessive inherited bleeding syndrome caused by quantitative and/or qualitative abnormalities in the platelet fibrinogen receptor, the αIIbβ3 integrin (glycoprotein (GP) IIb/IIIa, CD41/CD61) which mediates the incorporation of platelets into an aggregate or thrombus at sites of vessel injury [8, 9]. Laboratory parameters in severe GT show no platelet aggregation in response to all physiologic agonists and reduced or absent clot retraction. When these two findings are associated with normal platelet count and size, the diagnosis of GT is distinct. However, the diagnosis of GT should be confirmed by flow cytometry. In addition to quantitative determination of αIIbβ3, functional analysis of fibrinogen-binding capacity is essential. Therefore, specific monoclonal antibodies against fibrinogen (FITC fibrinogen) or activated αIIbβ3 (PAC-1) have to be applied [10, 11]. The detection of trace amounts of intracellular αIIb or β3, in a patient’s platelets by western blotting can give clues to the identity of the affected gene, while the presence of non-processed precursor pro-αIIbβ3 will suggest a block in the integrin biosynthesis [8]. GT is classified into 3 subtypes, depending on the level of present αIIbβ3. Patients with type I or classical GT are homozygous or compound heterozygous for the disease and have a virtual absence of αIIbβ3 (<5% of normal). Type II GT patients can have up to 25% of the normal level of complex. In the variant type, αIIbβ3 levels are near normal but functionally impaired, leading to defective binding of fibrinogen [12]. Heterozygotes for type I GT have approximately 50% of the normal level of platelet αIIbβ3 without bleeding problems. Using labor-intensive and time-consuming molecular genetic methods, a variety of mutations within the two genes for αIIb (ITGA2B) and β3 (ITG3B) have been identified (database: sinaicentral.mssm.edu/intranet/research/glanzmann). Hemorrhagic symptoms, such as mucocutaneous bleeding with epistaxis and purpura, gingival bleeding and menorrhagia, occur only in patients homozygous or compound heterozygous for GT. Heterozygous phenotypes with 50–70% functional αIIbβ3 show no significant reduction in platelet aggregation and are mostly asymptomatic [12]. The extent of bleeding depends on the amount of αIIbβ3; 20–30% functional αIIbβ3 seems to be sufficient to prevent severe bleeding [13].
Bernard-Soulier Syndrome

The Bernard-Soulier syndrome (BSS) is a rare autosomal recessive disease associated with bleeding tendency, giant platelets, and thrombocytopenia [14, 15]. Electron microscopy often shows many cytoplasmic vacuoles and zones enriched in membrane complexes in the giant platelets, abnormalities that extend to megakaryocytes (MKs). Based on data from Europe, North America, and Japan, the prevalence of homozygous BSS has been estimated at less than 1 in 1,000,000 [16] but is probably higher due to misdiagnosis and underreporting. According to the Hardy-Weinberg law, the frequency of the heterozygous phenotype is 1 in 500. The thrombocytopenia is due to quantitative and/or qualitative defects of the GPIb-IX-V complex. The glycoprotein (GP) Ib-IX-V complex on platelets initiates adhesion to vascular subendothelium at high shear stress by binding the adhesive ligand von Willebrand Factor (vWF). Patients with classical BSS are homozygous or compound heterozygous for mutations in the GPIα, GPIbβ, or GPIX genes [17–28]. Most of the mutations identified are point mutations that produce premature stop signals and unstable peptides. Missense mutations that affect functional domains are also widespread. In homozygous BSS bleeding, symptoms usually manifest rapidly after birth or during early childhood. Clinical manifestations usually include purpura, epistaxis, gingival bleeding and menorrhagia, and more rarely gastrointestinal bleeding and hematuria. Severe bleeding episodes are associated with surgery, dental extraction, menses, delivery, or accidents. However, the severity and frequency of bleeding symptoms vary between individuals, even within a single family. Heterozygous carriers are mostly asymptomatic but in some cases a mild to moderate bleeding tendency has been reported [29]. The initial laboratory assessment of BSS should involve measurement of blood cell counts and examination of a blood smear because a constant feature of BSS is the presence of a small number of very large platelets with a rounded shape (main volume 11–16 μm³) [30]. In homozygous patients, the platelet count ranges from 10,000 to 280,000/μl, and in heterozygous patients from very low (20,000/μl) to normal values, indicating that thrombocytopenia is a variable feature of this condition [18]. Manual counting is necessary for precise quantification because the very large platelets in BSS are often mistaken for lymphocytes in automatic cell counters. The distinctive abnormality in BSS is an isolated defect in ristocetin-induced aggregation. Platelet aggregation independent of the GPIb-IX-V/vWF interaction, such as that induced by collagen, adenosine diphosphate (ADP) or epinephrine, is usually within the normal range, however decreased responses to thrombin can be observed. The provisional diagnosis based on aggregometry should be confirmed by flow cytometry by using a panel of monoclonal antibodies (CD42a-d). Finally, molecular studies of genetic abnormalities allow precise definition of the platelet defect.

Platelet-Type or Pseudo-von Willebrand Disease

Platelet-type von Willebrand disease (PTvWD) is a rare autosomal dominant bleeding disorder caused by the increased affinity of the GPIbα receptor toward its ligand, vWF [31]. This promotes clearance of the larger vWF multimers from the blood and initiates a more rapid platelet turnover, causing mild macrothrombocytopenia. These clinical and laboratory features resemble those in patients with type 2B vWD except that the disorder is caused by an abnormal receptor rather than an abnormal ligand [32]. Patients have decreased factor VIII-ristocetin cofactor activity and enhanced platelet aggregation at low concentrations of ristocetin (≤0.5 mg/ml).

Deficient Collagen Receptor Functions

Deficient collagen receptor function has been described in several unrelated patients with mucocutaneous bleeding symptoms. GPIa-IIa (αIIbβ3) is a mediator of platelet adhesion to fibrillar collagens at sites of vascular injury. Platelets from a patient described by Nieuwenhuis et al. [33, 34] had a GPIa-IIa deficiency (15–25% of normal platelet GPIa) and failed to aggregate in response to collagen, or adhere and spread normally to subendothelial surfaces. Kehrel et al. [35] reported a patient with markedly reduced collagen-induced aggregation, and a deficiency in GPIa and thrombospondin. Selective impairment in collagen responses and a mild bleeding disorder have also been related to GPVI deficiency [36–38]. In a family with gray platelet syndrome and defective collagen adhesion, it was shown that the cause of abnormal platelet-collagen interaction is due to GPVI deficiency [39]. GPIV (CD36) has also been implicated in the collagen response. Platelet adhesion to collagen is reduced in the absence of functional GPIV, and this reduction occurs at the earliest stages of the adhesion process [40]. However, a single defect in GPIV may not result in clinical bleeding but may become symptomatic in combination with other defects such as autoantibodies against GPIa/IIa, GPIV, and/or GPIb/IIa [41]. 3–11% of the Japanese and approximately 0.3% of the US population have a lack of GPIV receptor and are asymptomatic [42, 43].

Enzyme Deficiencies

Some thrombocytopenias are caused by congenital deficiencies of cyclooxygenase-1, prostaglandin H synthetase-1, thromboxane synthetase, lipooxygenase, glycogen-6 synthetase, and enzymes of the adenosine triphosphate (ATP) metabolism.

Deficiency of Granule Stores: Storage Pool Disease (SPD)

This heterogeneous group of inherited disorders is characterized by variable reduction in the number and content of granules in megakaryocytes and platelets. The disorder is associated with mild or severe bleeding symptoms. It may present as an isolated platelet function defect, or be associ-
ated with a variety of congenital or acquired disorders. Platelets contain 4 main types of cytoplasmic granules classified according to their respective ultrastructures, densities, and content: the α-granules, the δ-granules (or δ-bodies), the lysosomes, and the peroxisomes. SPD platelets require the use of electron microscopy for reaching a definitive diagnosis.

δ-SPD patients lack δ-granules resulting in a deficiency of ADP, ATP, and serotonin, which when released, enhance platelet aggregation. Platelet aggregation studies typically show a significantly impaired second wave of aggregation when stimulated by ADP, epinephrine, or thrombin. The most consistent finding is that adenine nucleotides are reduced with an increased ratio of ATP to ADP and normal levels of lysosomal enzymes [44]. When platelet deficiencies of δ-granules are associated with abnormalities of other lysosome-related organelles, they cause clearly defined phenotypes. The best known are Hermansky-Pudlak syndrome (HPS), Griscelli syndromes, and Chediak-Higashi syndrome (CHS) where melanosomal defects result in a pattern of hypopigmentation [45].

More rarely, patients have α-SPD or the gray-platelet syndrome (GPS). In this defect, platelets appear gray on Wright-Giemsa-stained blood smears. Measurement of platelet ADP and ATP content and release are useful in the diagnosis of storage pool and release defects [46]. Most patients with GPS have a prolonged bleeding time and a bleeding diathesis that ranges from mild to severe, although life-threatening spontaneous hemorrhage is rare. Easy bruising, petechiae, mucosal membrane bleeding, and postsurgical or traumatic bleeding may occur. The Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder characterized by mildly reduced normal platelet counts, an epinephrine aggregation defect, multimerin deficiency, and proteolytic degradation of several soluble α-granular proteins [47, 48]. The fact that bleeding responds to fibrinolytic inhibitors rather than platelet transfusions led to the discovery that platelets in this disorder possessed unusually large amounts of urokinase-type plasminogen activator, a protein that is released on platelet activation [4, 49]. Combined αδ-granule deficiencies are less common than the isolated defects. In these defects, patients have marked deficiencies of δ-granules combined with variable reduction in platelet α-granules. Clinically, these patients behave much like α- or δ-SPD patients and respond to the same treatments.

**Macrotромбобластопения (Giant Platelet Syndromes)**

Inherited macrotромбобластопений comprise a group of heterogeneous diseases characterized by a reduction in the number but an increase in the volume of platelets with varying degrees of platelet dysfunction [50, 51]. The 4 most common defects – May-Heggelin anomaly, Fechtner syndrome, Sebastian syndrome, and Epstein syndrome – belong to the group of MYH9-related diseases affecting the non-muscle myosin heavy-chain IIA (myosin-IIA). Several of the giant platelet syndromes have associated membrane protein defects. For example patients with BSS as previously described have also giant platelets and mild thrombocytopenia. Since electronic counters measure platelets by enumerate platelets within a specified volume window (e.g. 2–20 fl), they fail to recognize the oversized platelets and therefore platelet count is underestimated. To overcome this problem in platelet counting, an immunological method using flow cytometry has been developed. This method, as ratified by the International Society of Laboratory Hematology (ISLH), is now the proposed international reference method (IRM) for counting platelets [52].

**Diagnostics and Differential Diagnosis**

**Suspicion of Bleeding Disorder – Diagnostic Strategy (Step 1)**

Currently, there are no guidelines regarding the diagnosis or treatment of patients with platelet function disorders. However, in daily practice physicians are frequently confronted with patients suffering from excessive bleedings or sometimes bleeding for no apparent reason. This comprises profuse and/or prolonged nose and gum bleeding, petechia, menorrhagia, or prolonged bleeding after cuts, abrasions, or injuries. Peri- and postoperative bleeding is also a frequently observed complication in the hospital setting. In these situations different questions must be asked: i) Is it a pathological bleeding or is the bleeding within the upper norm range? Mild bleeding disorders remain a challenge to diagnose because discrimination between normality and a pathological bleeding tendency is difficult. ii) Is the bleeding due to a congenital/familial or acquired disorder? iii) Which part of blood coagulation is affected – primary hemostasis (platelet or blood vessel wall problems) or secondary hemostasis (coagulation problems)? iv) Does the patient have a systemic disease that could cause or exacerbate the bleeding? v) Does the patient take any medication that may cause or exacerbate the bleeding tendency?

When the bleeding history and/or family history are suspicious, it is common practice to proceed to a staged series of investigations to confirm an abnormality of primary hemostasis or coagulation and to determine a precise diagnosis [53, 54]. Although in most cases a detailed anamnesis may be sufficient to distinguish between a platelet abnormality and coagulation abnormality (petechiae, mucocutaneous bleeding, delayed secondary bleeding, wound healing disorder), there is a general consensus that a few first stage tests: platelet counts, prothrombin time (PT), and activated partial thromboplastin time (aPTT) are carried out (table 2). To exclude congenital or acquired defects of plasmatic coagulation factors that influence primary hemostasis, in the first instance the vWF (because of vWD) and the fibrinogen level (because of hypo- or afibrinogenemia) have to be investigated (for further parameters see table 1). Thrombin time is not systematically performed but is considered as a screening test. The blood count
Diagnosis and Management of Inherited Platelet Disorders

Gregometry (LTA) is the gold standard for assessment of platelet function disorders. There are congenital platelet disorders exhibiting a characteristic aggregation pattern, e.g., primary aggregation abnormalities as in GT or secondary aggregation defects due to a low content of dense bodies, as observed in SPD. Platelet aggregation with at least ADP, collagen, arachidonic acid, and ristocetin should be used in the first step of screening (table 3). When a pathological value is measured in some of the screening tests, further investigations (stage 2) are necessary because different platelet functions (e.g., primary activation, adhesion and aggregation capability, platelet secretion, and procoagulant activity of platelets) may be affected in thrombocytopathy.

Further Analysis for Diagnostic Assessment (Stage 2)

In the case of pathological results for bleeding time, PFA-100, platelet aggregation, and/or a still unexplained bleeding tendency with the tests performed so far, further laboratory in-

**Table 2. Diagnostic approach to laboratory investigation (stage 1)**

<table>
<thead>
<tr>
<th>Test</th>
<th>Assessment</th>
<th>Material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood count incl. platelet count and mean platelet volume (MPV), blood smear</td>
<td>Detection/exclusion of thrombocytopenia, indication of giant platelet disorders</td>
<td>EDTA-anticoagulated whole blood; citrate-anticoagulated whole blood in the case of EDTA-dependent pseudothrombocytopenia</td>
</tr>
<tr>
<td>Coagulation tests: PT, aPTT, TT, FXIII, reptilase time, fibrinogen concentration, vWF antigen, ristocetin cofactor, collagen binding assay</td>
<td>Detection/exclusion of coagulation disorder. In case of prolonged PT/aPTT relevant factor assays should be performed, with inhibitor assay if indicated. A lupus inhibitor test should be performed in the view of isolated prolongation of the aPTT</td>
<td>plasma from citrated whole blood (citrated blood)</td>
</tr>
<tr>
<td>Standardized skin bleeding time</td>
<td>Prolonged bleeding time may be caused by drugs (e.g., acetylsalicylic acid) or is due to platelet function disorders</td>
<td>Mielke method, Duke method</td>
</tr>
<tr>
<td>Platelet function analyzer (PFA-100)</td>
<td>closure time is influenced by pre-analytical variables (platelet number, hematocrit, acetylsalicylic acid, and particularly vWF). Sensitivity is variable in congenital platelet disorders. The values are significantly prolonged in GT and BSS patients (closure time &gt; 300 s with collagen/ADP and epinephrine/collagen cartridges). In SPD, HPS and QPS patients, PFA may be sensitive but false-negative results can often occur</td>
<td>citrated blood</td>
</tr>
<tr>
<td>Platelet aggregation using the Born method or impedance aggregometry with: ADP, collagen, arachidonic acid, epinephrine, ristocetin in concentration series and limiting concentrations</td>
<td>Several thrombocytopathies have typical aggregation patterns (table 3). Also platelet inhibitors (e.g., acetylsalicylic acid, clopidogrel, or GP IIb/IIIa receptor antagonists) or other drugs such as high-dose ibuprofen and some antibiotics inhibit certain agonist-induced aggregations</td>
<td>platelet-rich plasma from citrated blood</td>
</tr>
</tbody>
</table>

aPTT = Activated partial thromboplastin time; BSS = Bernard-Soulier syndrome; GT = Glanzmann thrombasthenia; HPS = Hermansky-Pudlak syndrome; PT = prothrombin time; QPS = Quebec platelet syndrome; SPD = storage-pool-disease; TT = thrombin time; vWF = von Willebrand factor.

[55] The PFA-100® system (Siemens Healthcare Diagnostics, Deerfield, IL, USA) mimics an artificial vessel and consists of a capillary and a biologically active membrane with a central aperture coated with two agonists (either collagen plus ADP or collagen plus epinephrine). The PFA-100 device simulates primary hemostasis at high shear and is therefore particularly sensitive to decreased vWF levels but also to some platelet disorders. In the platelet function disorders, its use as a screening test is a matter of more controversy, particularly because PFA-100 is poorly sensitive to platelet secretion defects which represent the most common abnormalities of platelet function. Light transmission aggregometry (LTA) is the gold standard for assessment of platelet function disorders. There are congenital platelet disorders exhibiting a characteristic aggregation pattern, e.g., primary aggregation abnormalities as in GT or secondary aggregation defects due to a low content of dense bodies, as observed in SPD. Platelet aggregation with at least ADP, collagen, arachidonic acid, and ristocetin should be used in the first step of screening (table 3). When a pathological value is measured in some of the screening tests, further investigations (stage 2) are necessary because different platelet functions (e.g., primary activation, adhesion and aggregation capability, platelet secretion, and procoagulant activity of platelets) may be affected in thrombocytopathy.
vestigation is required (stage 2). Many of these tests can be very expensive, time-consuming, and need to be carried out in specialized hemostaseologic laboratories. However, it is not recommended to use shipped blood samples for analysis of platelet function because the measurements are dependent on the age of the blood samples. Therefore, patients often have to be examined on-site in hemostaseologic laboratories. Also in these cases, the physician should keep in mind that the results are influenced by preanalytical variables such as difficult venepuncture, undisclosed drug contamination (acetylsalicylic acid, heparin), and excessive citrate concentrations due to erythrocytosis. A further important point is that for most laboratory tests normal values are established using the mean value and 2 standard deviations from a representative population. Consequently, 2.5% of normal subjects will have a slightly prolonged clotting time.

Flow cytometric methods with specific monoclonal antibodies are used for qualitative and quantitative analysis of important surface receptors, e.g. GPIIb/IIIa, GPIb/IX/V, GPIIa/IIa, and GPIXlb. For example, the function of GPIIb/IIIa is analyzed after ADP or TRAP (thrombin receptor activating protein) stimulation using fluorescein-isothiocyanate-(FITC)-labeled anti-fibrinogen antibody or PAC-1 (procaptase activating compound 1) directed against activated GPIIb/IIIa. With the help of flow cytometric analysis, some activation and secretion defects can be detected by preparing concentration series of activators and measuring the granule receptors (secretion marker) CD62 (α-granule) and CD63 (δ-granule). Flow cytometry is also capable of detecting signal transduction defects in platelets. For this purpose, phosphorylation-specific antibodies have been developed that measure the phosphorylation state of specific intracellular platelet proteins, e.g. VASP (vasodilator-stimulated phosphoprotein) or MAP kinase (mitogen-activated protein). In addition, with flow cytometric analysis of mepacrine-labeled platelets the mitogen-activated protein (MAP) kinase (mitogen-activated protein). In addition, with flow cytometric analysis of mepacrine-labeled platelets and measuring the granule receptors (secretion marker) CD62 (α-granule) and CD63 (δ-granule). Flow cytometry is also capable of detecting signal transduction defects in platelets. For this purpose, phosphorylation-specific antibodies have been developed that measure the phosphorylation state of specific intracellular platelet proteins, e.g. VASP (vasodilator-stimulated phosphoprotein) or MAP kinase (mitogen-activated protein). In addition, with flow cytometric analysis of mepacrine-labeled platelets the (reduced) content of δ-granules in anucleate platelets can be demonstrated as mepacrine binds particularly to adenine nucleotides. After a further activation step, the (impaired) secretion of δ-granules can also be assessed.

The (reduced) content and (impaired) secretion of α- and δ-granules may also be detected on the basis of release products (e.g. platelet factor 4, PDGF, ATP/ADP, or serotonin) by ELISA or luminometry (firefly method). The content of δ-granules may also be evaluated by electron microscopy. For this, a drop of platelet-rich plasma (PRP) is placed on a coated grid, washed with distilled water, dried with wedges of filter paper, and then inserted into the electron microscope. δ-granules appear as dark spots and can be counted.

Adhesion and spreading disorders are investigated by adhesion and spreading tests. Platelet adhesion to different surfaces such as collagen, fibrinogen, siliconized glass, and subendothelial matrix is evaluated. Platelet spreading is analyzed by light microscopy by measuring platelet size and volume. This method is also capable of detecting giant platelets. The special tests of stage 2 are summarized in table 4.

In addition to the above mentioned tests, a lot of other tests can be done. For example, over the past years the thrombin generation test has emerged as a universal method for measuring hemostatic disorders. Evidence is growing that the parameters of the thrombogram, and notably the area under the curve (endogenous thrombin potential, ETP), are useful in assessing risk of both bleeding and thrombosis [56]. However, this assay has no proven place as a screening test for bleeding disorders in general so far, but we think that this test could be particularly useful in understanding why with the same hemostatic abnormality some subjects bleed whereas others do not bleed.

**Prophylaxis and Treatment of Bleeding in Patients with Platelet Disorders**

Patients with congenital and acquired thrombocytopenias/-penies may require transfusion of blood products (e.g. platelet concentrates, PC) in the course of their life. Due to the infection risk, patients should be vaccinated against hepatitis A and B. Moreover, in thrombocytopenias/-penies with severe bleeding tendency the human leukocyte antigen (HLA) type should be determined so that patients can receive HLA-matched transfusions with minimized immunization risk. Patients should carry an emergency health card with information about the disease, therapy, contraindications (antiplatelet drugs), as well as the telephone number of the attending physician.

---

**Table 3. Differential aggregation responses in patients with thrombocytopenias**

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>ADP</th>
<th>Collagen</th>
<th>Arachidonic acid</th>
<th>Ristocetin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glanzmann thrombasthenia</td>
<td>▼ – Ø</td>
<td>▼ – Ø</td>
<td>▼ – Ø</td>
<td>n – ▼</td>
</tr>
<tr>
<td>Bernard-Soulier syndrome</td>
<td>n ▼</td>
<td>n</td>
<td>n</td>
<td>▼ – Ø</td>
</tr>
<tr>
<td>May-Hegglin syndrome</td>
<td>n – (▼)</td>
<td>n</td>
<td>?</td>
<td>n</td>
</tr>
<tr>
<td>δ-Storage pool disease</td>
<td>n ▼</td>
<td>▼</td>
<td>n – ▼</td>
<td>n – ▼</td>
</tr>
<tr>
<td>α-Storage pool disease</td>
<td>n ▼</td>
<td>▼</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>Aspirin-like defect</td>
<td>▼</td>
<td>▼</td>
<td>▼</td>
<td>n</td>
</tr>
</tbody>
</table>

n = Normal; Ø = absent; ▼ = inhibited or reduced; (▼) = slightly inhibited.
ing, menorrhagia, or gastrointestinal bleeding tranexamic acid is given orally (usually 2–3 times 1,000–1,500 mg daily) or intravenously as monotherapy or additional therapy. However, an important disadvantage of tranexamic acid is its low bioavailability of about 30%, necessitating frequent intake of high doses.

Desmopressin

The vasopressin analog desmopressin (1-desamino-8-D-arginine vasopressin; Minirin®, Ferring, Saint-Prex, Switzerland) shortens the bleeding time in storage pool deficiencies. Desmopressin can be administered parenterally either via intravenous or subcutaneous injection or intranasally as drops or spray. The recommended parenteral dose is 0.3 μg/kg body

Table 4. Further analysis (stage 2) for diagnostic assessment of thrombocytopathies/-penias (depending on the results of the first stage investigations)

<table>
<thead>
<tr>
<th>Test</th>
<th>Assessment/detection</th>
<th>Material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repetition of platelet aggregation from stage 1 (see table 1)</td>
<td>verification of results; if results are suggestive, perform platelet granule secretion assay</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Flow cytometry</td>
<td>reduced/absent GP-IIb/IIIa receptor (Glanzmann thrombasthenia) or GP-Ib/IX/V receptor (Bernard-Soulier syndrome)</td>
<td>PRP from citrated blood; determination of receptor count is possible in 1- to 2-days-old blood samples given that a healthy controls sample was also sent to the laboratory; functional measurements should be performed within 3 h after PRP preparation</td>
</tr>
<tr>
<td>Platelet receptors: e.g. GP-IIb/IIIa, GP-Ib/XI/V</td>
<td>reduced fibrinogen binding of GP-IIb/IIIa</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Functional PAC-1 or fibrinogen binding to GP-IIb/IIIa</td>
<td>activation- and/or secretion-deficiency</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Activation marker: CD62 (receptor of α-granules) CD63 (receptor of δ-granules)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mepacrine staining</td>
<td>reduced/absent δ-granules</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Signal transduction: VASP, MAP kinase</td>
<td>phosphorylation defects</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Other procedures</td>
<td>adhesion to different surfaces (siliconized glass, collagen, fibrinogen, subendothelial matrix); defects in Glanzmann thrombasthenia, Bernard-Soulier syndrome, different giant platelets thrombocytopathies</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Platelet adhesion (microscopically)</td>
<td>PRP from citrated blood</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Platelet spreading (microscopically)</td>
<td>size of platelets</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Volume distribution (microscopically, cell counter), blood smear</td>
<td>giant platelets (Bernard-Soulier syndrome, May-Hegglin anomaly), leukocytes inclusions (May-Hegglin anomaly and related diseases)</td>
<td>PRP from citrated blood, EDTA-anticoagulated whole blood</td>
</tr>
<tr>
<td>Plasma exchange test, MAIPA (monoclonal antibody immobilization of platelet antigens test)</td>
<td>detection of platelet antibodies in acquired autoantibody induced thrombocytopenia/thrombocytopathy</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Platelet granule-secretion assay, luminometry (firefly method), ELISA (serotonin detection)</td>
<td>ATP content and ATP secretion, serotonin-content (δ-storage pool disease)</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>ELISA (PF4, PDGF, β-thromboglobulin)</td>
<td>PF4-, PDGF-, β-thromboglobulin-content (α-storage pool disease)</td>
<td>PRP from citrated blood</td>
</tr>
<tr>
<td>Electron microscopy of platelets</td>
<td>α- or δ-storage pool defect; particularly δ-granules are presentable with easy preparation technique</td>
<td>PRP from citrated blood</td>
</tr>
</tbody>
</table>

Local Measures

Local bleeding, such as nose or gum bleeding, in patients with platelet disorders may usually be stopped with conservative local measures including nose pads and/or fibrin sealants which contain fibrinogen, thrombin, factor XIII and aprotinin, or fibrin-coated collagen fleece. Proper oral hygiene is important to prevent gum bleeding. In the case of gum bleeding, mouth rinse with tranexamic acid can be helpful.

Systemic Antifibrinolytic Therapy

Antifibrinolytic agents, such as tranexamic acid, are effective in the management of bleeding in patients with thrombocytopathy/-penia. For the treatment of mucocutaneous bleeding
weight, and the intranasal dose is 300 μg. Desmopressin stimulates the release of endothelial vWF and enhances platelet adhesion to the vessel wall. The effectiveness of desmopressin for prevention and treatment of bleeding was also shown in other thrombocytopathies. However, response to desmopressin is highly variable among patients with different platelet disorders and may not be sufficient. In patients with receptor defects, e.g. GT, therapy with desmopressin is not effective. In patients with thrombocytopenia, desmopressin does not shorten the bleeding time. Side effects of desmopressin include flushing, changes in blood pressure, hypersensitivity reactions (rash, fever, bronchospasm), fluid retention, and/or hyponatremia. Fluid intake should be adjusted to reduce the possibility of water intoxication and hyponatremia especially in very young and elderly patients. Particular attention should be paid to the risk of an extreme decrease in plasma osmolality and resulting seizures in young children. However, seizures may also occur without fluid retention. The antiuridiuretic effect of desmopressin is increased by clofibrate, indomethacin, carbamazepine, chlorpropamide, and tricyclic antidepressants.

Platelet Concentrates

A general indication for the transfusion of PCs is thrombocytopenic bleeding due to a platelet production defect or consumption/dilutional coagulopathy. In addition, severe bleeding complications or non-response to desmopressin after surgery or trauma justify the administration of PCs. Prophylactic administration of PCs in idiopathic thrombocytopenic purpura (ITP) is not recommended. Specific indications for platelet transfusions are: i) bleeding complications in inherited platelet disorders (e.g. GT, BSS); ii) emergency therapy of thrombocytopenic/-pathic bleeding in patients with disorders of megakaryopoiesis or increased platelet turnover (e.g. ITP, liver disease, or DIC); iii) thrombocytopenia after massive transfusion; iv) prophylaxis in thrombocytopenic/-pathy and bleeding risk as well as preoperative [57]. The PC dosage is dependent on the patient’s clinical condition, the extent of the thrombocytopenia, the target value of the platelet number, and factors that influence platelet survival time and platelet function. One unit of platelets (2–4 × 10^11 platelets) would be expected to increase the platelet count of an adult patient (70 kg) by 20,000–30,000/μl. Young children and newborns should receive 10 ml PC/kg body weight. The efficacy of platelet transfusion is assessed on the basis of the clinical effect (hemostasis), the increase in the number of platelets, and possibly on the basis of platelet function (e.g. bleeding time). Immunological or non-immunological refractoriness may be the cause of an insufficient increment in the platelet count after transfusion. Immunological refractoriness is primarily caused by HLA antibody-mediated destruction of transfused platelets, although HPA and high-titer ABO alloantibodies have occasionally been implicated. In such a case not only ABO- but also HLA-compatible platelets should be given. Patients with GT have a particularly high risk for alloimmunization. Prevention is best accomplished by using leukocyte-depleted blood products. Use of platelets matched via HLA is a further attempt to prevent platelet alloimmunization.

Recombinant Activated Factor VIIa (rFVIIa)

rFVIIa (NovoSeven®, Novo Nordisk Inc., Bagsvaerd, Denmark) is often used in thrombocytopathic/-penic patients suffering from bleeding that can not be stopped by conventional treatments. Best reported data concerning the efficacy of rFVIIa is documented in thrombasthenic patients. Poon et al. [58] analyzed the data of an international registry for the treatment and prophylaxis of patients with GT and found that prophylaxis with rFVIIa in 29 out of 31 thrombasthenic patients undergoing surgery was effective. On the basis of this study, European approval for rFVIIa was obtained for thrombasthenic patients with antibodies against GPIIb/IIIa and/or HLA and with refractoriness to platelet transfusion therapy. Patients with GT receive at least 3 bolus injections at doses of 80–120 μg/kg body weight every 1.5–3 h until hemostasis [59]. Recently, a single dose of 270 μg/kg was approved in Europe on the basis of a study comparing 90 μg/kg three times per bleed with one single bolus of 270 μg/kg. In the meantime, the above-mentioned dosage (at least 3 bolus doses of 80–120 μg/ kg rFVIIa) is also used for the treatment of severe bleeding complications in patients with BSS, storage pool diseases, and several acquired thrombocytopathies. In approximately half of the patients with thrombocytopenias, a single bolus of rFVIIa has been shown to be sufficient in managing otherwise untreatable bleeding complications. In these patients, hemostasis was achieved even at platelet counts <20,000/μl, although the efficacy of rFVIIa increases at higher platelet counts [60, 61]. Case reports reveal that the use of rFVIIa is more effective when administered early in a bleeding episode than it is when administered late. In 28 acute bleeding episodes in 7 children with platelet disorders (5 GT, 1 BSS, 1 SPD) 73% of the bleedings could be stopped when rFVIIa was administered <12 h from onset of bleeding. Presentation >12 h from onset of bleeding was an unfavorable feature; only 25% had an excellent or good response [61, 62]. Whether further bolus injections of rFVIIa are necessary after successful hemostasis has to be decided empirically in each case [61]. Today, the therapeutic application of rFVIIa in patients with thrombocytopenia of different origin is largely empirical. There are only a few casuistics with rFVIIa alone or in combination with PCs available reporting about successful treatment. The use of rFVIIa in thrombocytopenia should be limited to life-threatening or conservative non-treatable bleeding complications. However, to increase the effect of rFVIIa, a prompt transfusion of PC should be considered taking into account the risk-benefit ratio [60, 61].
Bone Marrow Transplantation

Since 1985, only a few patients with severe GT, Wiskott-Aldrich syndrome, or CRS have undergone bone marrow transplantation resulting in normalization of platelet function and megakaryopoiesis.

Conclusion

The inherited platelet function defects are a heterogeneous collection of rare bleeding disorders with symptoms that range in severity from mild to life-threatening. The precise diagnosis of a platelet function defect remains a challenge, even for specialists. Despite advances in the understanding of the etiology of these defects, in the vast majority of patients with inherited platelet disorders, the underlying mechanisms remain unknown. The treatment of platelet function disorders will depend on the particular type of disorder as well as the severity of the bleeding. Transfusion of platelets remains the primary therapy of severe bleeding. Alternatively, rFVIIa (90–120 μg/kg bolus infusion) can be given. In contrast to receptor defects (GT), platelet function defects (storage pool diseases) can be treated with desmopressin (0.3 μg/kg body weight intravenously, or in the case of mild bleeding with Octostim® spray (Ferring)) and/or cyclokapron (tranexamic acid 20 mg orally).

Disclosure

The authors declared no conflict of interest.

References


55 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152–63.


59 NovoSeven® – recombinant factor VIIIa Novo Nordisk’s EU Package Insert.

